Phase 3 breast cancer failure leads to staff cuts, stock drop at G1 Therapeutics
G1 Therapeutics said its lung cancer drug Cosela didn’t fare better than a placebo in extending the lives of breast cancer patients.
In the Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
